SLITRK6 and urothelial carcinoma: An antibody to the SLITRK6 protein has been linked with a cytotoxic agent monomethyl auristatin E (AGS15E) and is currently in phase I clinical trials for patients with metatstatic urothelial carcinoma (protocol ID NCT 01963052)[17].